Stellanova Therapeutics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stellanova Therapeutics Closes $15.5M Series A Financing Round The round was led by Sporos Bioventures. The company intends to use the funds to advance its lead antibody asset to first-in-human clinical trials for oncology, establish its discovery platform, and build its team. Led by Rosa Hwang, M.D., co-founder, Stellanova is focused on targeting the many pro-tumorigenic effects enabled by the activity of carcinoma-associated fibroblasts (known as CAFs) in the tumor microenvironment. CAFs play essential roles in promoting cancer growth and metastasis, spurring angiogenesis, suppressing anti-tumor immunity, and fostering chemoresistance. The company’s lead antibody candidate is designed to neutralize DKK3, a factor secreted by CAFs that acts on neighboring cancer cells and immune cells to promote tumor progression and therapy resistance. In pre-clinical studies, treatment with anti-DKK3 monoclonal antibody and immune checkpoint inhibitor therapy has produced sustained tumor era

United statesRosa hwangSporos bioventuresEmmanuelle schulerHouston texas medical centerStellanova therapeutics incStellanova therapeuticsChief executiveCorallis consultingTexas medicalஒன்றுபட்டது மாநிலங்களில்ரோசா ஹ்வ்யாஂக்இம்மானுவேல் ஸ்கூலர்ஹூஸ்டன் டெக்சாஸ் மருத்துவ மையம்தலைமை நிர்வாகிடெக்சாஸ் மருத்துவ